SCHEMBL1747335

SCHEMBL1747335

COC(=O)CCc1ccc(OC2Cc3ccccc3C2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.47
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.45
OPRM1 P35372 1/20 0.45
OPRD1 P41143 1/20 0.45
ADRB2 P07550 2/20 0.44
ADRB1 P08588 1/20 0.43
F2RL1 P55085 1/20 0.43
NPC1 O15118 1/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ADRA1D P25100 1/20 0.43
ADRA1A P35348 1/20 0.43
ADRA1B P35368 1/20 0.43
EPHX2 P34913 5/20 0.42
HRH3 Q9Y5N1 1/20 0.42
POLB P06746 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1744897 0.85 FFAR1 (0.58) FFAR1EPHX2
SCHEMBL1744681 0.79 FFAR1 (0.52) FFAR1ALDH1A1ADRB2ADRB1NPC1
SCHEMBL1744692 0.79 FFAR1 (0.52) FFAR1ALDH1A1ADRB2ADRB1NPC1
SCHEMBL1745225 0.79 FFAR1 (0.52) FFAR1ALDH1A1ADRB2ADRB1NPC1
SCHEMBL1746463 0.77 FFAR1 (0.53) FFAR1ALDH1A1ADRB2ADRB1SMN1; SMN2
SCHEMBL1744972 0.77 EPHX2 (0.39) ALDH1A1LMNAOPRM1OPRD1ADRB2
SCHEMBL1747359 0.77 FFAR1 (0.51) FFAR1ALDH1A1ADRB2ADRB1HRH3
SCHEMBL27608053 0.76 EPHX2 (0.43) ALDH1A1LMNAOPRM1OPRD1ADRB2
SCHEMBL3497927 0.76 FFAR1 (0.55) FFAR1LMNAADRB2EPHX2
SCHEMBL22922181 0.75 CYP4F2 (0.59) ALDH1A1LMNAADRB2ADRB1F2RL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR FFAR1 33/4885ALDH1A1 4258/4885LMNA 4714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.